BioCentury
ARTICLE | Clinical News

BNC105: Interim Phase I/II data

August 8, 2011 7:00 AM UTC

Interim data from the Phase I portion of an open-label, dose-escalation, U.S. Phase I/II trial in patients who failed prior tyrosine kinase inhibitor (TKI) therapy showed that 12.6 mg/m 2 BNC105 plus Afinitor everolimus for >=12 cycles of treatment was well tolerated. Bionomics said the results warrant continuation of the trial to complete evaluation of the 16 mg/m 2 dose of BNC105 in combination with Afinitor and to proceed into the Phase II portion of the trial. ...